Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FLT3-ITD mutation
i
Other names:
FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2322
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
LeukoStrat® CDx FLT3 Mutation Assay (6)
LeukoStrat® CDx FLT3 Mutation Assay (6)
Associations
(90)
News
Trials
Search handles
@AaronGoodman33
@NicholasShortMD
@PLMcCarthyMD
@i_yakoub_agha
@smbenlazar
Search handles
@AaronGoodman33
@NicholasShortMD
@PLMcCarthyMD
@i_yakoub_agha
@smbenlazar
Filter by
Latest
8ms
#regulatory #news ~@Invivoscribe nabs #FDAApproval of mutation assay to patients with FLT3-ITD Positive #AML ~#NecteroMedical receives clearance of IND to initiate trial of Nectero EAST® System ~@Nesa_Medtech receives clearance for fibroid #mapping reviewer application (@MedTechNow_)
8 months ago
Clinical • FDA event
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
1year
Leukemia docs lets discuss! A 50 year old with FLT3 ITD and NPM1 mutated AML is treated with 7+3+midostaurin achieving CR. Both NPM1 and FLT3 ITD are no longer detectable. Proceeds with ablative MUD. Post allo is still in MRD- CR at day+50 and is doing well. You recommend? (@AaronGoodman33)
1 year ago
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • NPM1 mutation
|
Rydapt (midostaurin)
1year
This is a young fit pt with ELN fav AML (NPM1 mutant, FLT3 ITD negative), if achieves MRD_neg CR1, would not necessarily txp. NPM1 is now AML defining (regardless of blasts) so standard IC, not HMA/ven (experimental in this setting). (@LuskinMarlise)
1 year ago
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • FLT3 mutation • NPM1 mutation
1year
Leukemic and transplant experts! Otherwise healthy patient AML in CR1 after treatment with 7 plus 3 plus midostaurin. Mutation profile FLT3 ITD+/NPM1+/DNMT3A+. No detectable mutations on NGS panel after induction. Good MUDs available. Would anyone not transplant? (@AaronGoodman33)
1 year ago
Clinical • Next-generation sequencing
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1)
|
FLT3-ITD mutation • NPM1 mutation • DNMT3A mutation
|
Rydapt (midostaurin)
1year
AML Heme Path Pearl! AML with t(6;9) [DEK-NUP214] 1% of AMLs Associated with basophilia! Frequent FLT3 ITD mutations Poor prognosis (5 year OS = 30%) Rx = intensive induction +/- FLT3 inhibitor or ven/aza Consolidate = allogeneic transplant if able. https://t.co/LDmZ7I09oZ (@AaronGoodman33)
1 year ago
FLT3 (Fms-related tyrosine kinase 3) • NUP214 (Nucleoporin 214) • DEK (DEK Proto-Oncogene)
|
FLT3-ITD mutation
over1year
ACUTE MYELOID LEUKEMIA HIGHLY ASSOCIATED WITH FLT3-ITD AND NPM1 mutations CUPLIKE NUCLEI (PROMINENT NUCLEAR INVAGINATIONS) (@Sthanu5)
over 1 year ago
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • NPM1 mutation • FLT3‐ITD + NPM1 mutation
over1year
Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission https://t.co/yXfeHgQA5T (@DrChrisHourigan)
over 1 year ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • NPM1 mutation
over1year
In 454 patients transplanted 2013-2018 we clearly show clinical utility for residual FLT3-ITD and/or NPM1 mutation testing pre-alloHCT. This is definitive and the largest dataset of AML NGS-MRD put together & has advantage of being focused on specific subset and context of use. ()
over 1 year ago
Clinical • Next-generation sequencing
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • NPM1 mutation
|
NPM1 Mutation Assay
over1year
Değerli Dostlar, #Akutlösemi’de genetik testler ne kadar önemli? FLT3-ITD mutasyonlu CBF-AML'li hastalar 'olumlu risk' olarak sınıflandırılmalı mı? Bu mutasyonların prognostik etkisine ilişkin en son veriler ne diyor? Keyifle okumalar #profdrfevzialtuntas https://t.co/ijk6jw9qWL (@altuntasfevzi)
over 1 year ago
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
over1year
Cup-like blasts in AML There is a close relationship of CLB-AML with specific molecular aberrations. NPM1-mutation and/or FLT3-ITD individually or in combination are present in >60% of CLB-AML with normal karyotype (NK). https://t.co/FE8rGzT9yq (@salmanf)
over 1 year ago
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • FLT3 mutation • NPM1 mutation
almost2years
Great data on HMA + ven + quizartinib in FLT3-ITD mutated AML from @MusaYilmazMD. Response rate of 80% is particularly impressive for patients with prior gilteritinib exposure. We still need better therapies for patients with RAS pathway mutations though. @Daver_Leukemia (@NicholasShortMD)
almost 2 years ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
|
Xospata (gilteritinib) • Vanflyta (quizartinib)
almost2years
AML Question A 72 year old who is fit for induction is diagnosed with FLT3 ITD mutated (high allelic ratio) NPM1 wildtype AML. You recommend? @Daver_Leukemia @Dr_AmerZeidan (@AaronGoodman33)
almost 2 years ago
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • NPM1 mutation
almost2years
Imagine it's the year 2018 in the USA. Would you enroll your patient with FLT3 ITD mutated AML on a randomized trial of a new FLT3 inhibitor plus 7+3 vs 7+3+placebo? (@AaronGoodman33)
almost 2 years ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
2years
Leukemia Question! A 74 year old with FLT3 ITD mutated AML relapses 1 year after treatment with 7+3+midostaurin. At relapse NGS revealed FLT3 ITD and no other alterations. They are not an allo transplant candidate. You recommend? (@AaronGoodman33)
2 years ago
Next-generation sequencing
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
|
Rydapt (midostaurin)
2years
Very nice summary. Interesting that pts with NUP98 fusions (another nucleoporin) also have very high rate of FLT3 ITD mutations (in the range of 75% - see Struski S, Leukemia 2017). There is probably some synergy between Nup fusions and Flt3 mutations. (@fabiopss)
2 years ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • NUP98 (Nucleoporin 98 And 96 Precursor 2)
|
FLT3-ITD mutation • FLT3 mutation
2years
AML Question! 70 year old patient with no major medical co-morbidities presents with pancytopenia. Bone marrow biopsy reveals AML with a normal karyotype. Mutation analysis reveals NPM1+ and negative for FLT3 ITD/TKD. A TET2 mutation was also identified. You recommend... (@AaronGoodman33)
2 years ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
|
FLT3-ITD mutation • NPM1 mutation • TET2 mutation
2years
AML Heme Path Pearl! AML with t(6;9) [DEK-NUP214] 1% of AMLs Associated with basophilia! Frequent FLT3 ITD mutations Poor prognosis (5 year OS = 30%) Rx = intensive induction +/- FLT3 inhibitor or ven/aza Consolidate = allogeneic transplant if able. https://t.co/LDmZ7HI0aR (@AaronGoodman33)
2 years ago
FLT3 (Fms-related tyrosine kinase 3) • NUP214 (Nucleoporin 214)
|
FLT3-ITD mutation
2years
Just came out. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated AML patients: On behalf of ALWP @TheEBMT @Mohty_EBMT @BldCancerDoc @SFGM_TC @CChabannon https://t.co/jDJuNaMDhb (@i_yakoub_agha)
2 years ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
over2years
At an interesting AML oral abstract session! Newly diagnosed FLT3 ITD mutated/NPM1 negative, no TP53, normal karyotype patient who is fit for chemo but age 68. What do you recommend??? #ASH21 @Dr_AmerZeidan @LeukDocJZ @Daver_Leukemia (@AaronGoodman33)
over 2 years ago
Clinical
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
TP53 mutation • FLT3-ITD mutation • NPM1 mutation
over2years
Yes tough decision. I’m a transplanter and leukemia doc and if I were FLT3 ITD < 0.5 NPM1 mutated and achieved CR I would not want to go to allogeneic transplant and would choose HiDAC plus midostaurin consolidation for myself. (@AaronGoodman33)
over 2 years ago
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • NPM1 mutation
|
Rydapt (midostaurin)
almost3years
Cup-shaped nuclei in NPM1-mutated and FLT3-ITD+ AML. Morphologic identification can expedite molecular testing for treatment and clinical trial enrollment. #hemepath @NU_Pathology @LurieCancer @jaltmanmd (@AmirBehdadMD)
almost 3 years ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • FLT3 mutation • NPM1 mutation
almost3years
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin | Blood | American Society of Hematology https://t.co/7WWWMAAKYH (@PLMcCarthyMD)
almost 3 years ago
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
|
Rydapt (midostaurin)
over3years
Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) #AML: Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial | Blood | American Society of Hematology #leusm @doctorpemm https://t.co/AJqNL7DLog (@smbenlazar)
over 3 years ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
|
Venclexta (venetoclax) • Vanflyta (quizartinib) • decitabine
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login